Jennifer Michaelson Sells 11,742 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) insider Jennifer Michaelson sold 11,742 shares of the business’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $14.08, for a total transaction of $165,327.36. Following the completion of the sale, the insider directly owned 181,977 shares of the company’s stock, valued at approximately $2,562,236.16. The trade was a 6.06% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jennifer Michaelson also recently made the following trade(s):

• On Thursday, February 12th, Jennifer Michaelson sold 416 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $5,004.48.
• On Thursday, January 22nd, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.30, for a total transaction of $49,200.00.
• On Friday, December 19th, Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $10.01, for a total transaction of $13,463.45.
• On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $9.67, for a total transaction of $28,023.66.
• On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $11.90, for a total transaction of $11,840.50.
• On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $12.38, for a total transaction of $26,592.24.

Cullinan Therapeutics Trading Up 2.0%

CGEM stock opened at $14.27 on Wednesday. Cullinan Therapeutics, Inc. has a 12-month low of $5.68 and a 12-month high of $14.56. The business’s 50-day moving average is $11.41 and its 200 day moving average is $9.27. The stock has a market cap of $843.01 million, a price-to-earnings ratio of -4.31 and a beta of -0.09.

Analyst Ratings Changes

Several research analysts recently commented on CGEM shares. Wall Street Zen downgraded Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a report on Thursday, November 20th. Citigroup initiated coverage on shares of Cullinan Therapeutics in a research report on Tuesday, February 17th. They issued a “buy” rating and a $33.00 target price for the company. Wedbush boosted their price target on shares of Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cullinan Therapeutics in a research note on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $29.33.

Institutional Investors Weigh In On Cullinan Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. boosted its holdings in Cullinan Therapeutics by 27.4% in the 4th quarter. Invesco Ltd. now owns 130,323 shares of the company’s stock valued at $1,349,000 after purchasing an additional 28,011 shares during the last quarter. Virtus Investment Advisers LLC increased its holdings in shares of Cullinan Therapeutics by 75.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 22,318 shares of the company’s stock worth $231,000 after buying an additional 9,604 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its position in shares of Cullinan Therapeutics by 87.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 233,842 shares of the company’s stock valued at $2,420,000 after buying an additional 109,311 shares during the period. Elmind Capital LP purchased a new stake in shares of Cullinan Therapeutics during the 4th quarter valued at approximately $3,208,000. Finally, Engineers Gate Manager LP lifted its holdings in Cullinan Therapeutics by 37.7% in the fourth quarter. Engineers Gate Manager LP now owns 69,343 shares of the company’s stock valued at $718,000 after acquiring an additional 18,980 shares during the last quarter. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Cullinan Therapeutics

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: Bullish independent thesis — A Seeking Alpha write‑up upgrades Cullinan to a Buy, highlighting a deep T‑cell engager pipeline (notably CLN‑049 showing ~30% CR in AML), a strong cash runway (~$430M+), and a clear regulatory path that supports upside expectations. Seeking Alpha: Thesis Strengthening For This T-Cell Engager Specialist
• Positive Sentiment: Investor conference participation — Management (CEO Nadim Ahmed and CMO Jeffrey Jones) announced attendance at upcoming investor conferences, which increases investor access to clinical updates and can support multiple‑stakeholder visibility. GlobeNewswire: Cullinan Therapeutics to Participate in Upcoming Investor Conferences
• Positive Sentiment: Analyst momentum — Multiple firms have issued Buy/Outperform ratings and lifted price targets in recent months (consensus/average target materially above current levels), which can attract momentum buyers. MarketBeat: CGEM analyst coverage
• Neutral Sentiment: Technical/fundamental backdrop — The stock is trading above the 50‑ and 200‑day moving averages and is well above its 52‑week low, reflecting short‑term strength; market cap and high institutional ownership (~86%) mean moves can be amplified by flows. MarketBeat: CGEM profile
• Negative Sentiment: Clustered insider sales — Several insiders (CEO Nadim Ahmed, CFO Mary Kay Fenton and others) sold shares around Feb 20 (combined ~20k+ shares across multiple filings). While the percentages trimmed are modest (low single digits), simultaneous sales by senior executives can create near‑term selling pressure and raise questions for some traders. InsiderTrades: CGEM insider transactions

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.